Blocking interleukin-1beta in acute and chronic autoinflammatory diseases.
SourceJournal of Internal Medicine, 269, 1, (2011), pp. 16-28
1 januari 2011
Article / Letter to editor
Display more detailsDisplay less details
Journal of Internal Medicine
SubjectN4i 1: Pathogenesis and modulation of inflammation
An expanding spectrum of acute and chronic inflammatory diseases is considered 'autoinflammatory' diseases. This review considers autoinflammatory diseases as being distinct from 'autoimmune' diseases. Autoimmune diseases are associated with dysfunctional T cells and treated with 'biologicals', including antitumour necrosis factoralpha, CTLA-Ig, anti-IL-12/23, anti-CD20, anti-IL-17 and anti-IL-6 receptor. In contrast, autoinflammatory diseases are uniquely attributed to a dysfunctional monocyte caspase 1 activity and secretion of IL-1beta; indeed, blocking IL-1beta results in a rapid and sustained reduction in the severity of most autoinflammatory diseases. Flares of gout, type 2 diabetes, heart failure and smouldering multiple myeloma are examples of seemingly unrelated diseases, which are uniquely responsive to IL 1beta neutralization.
Upload full text